Search
for
Sort by
Research 30 of 297
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Nilotinib-Induced Keratosis Pilaris
- A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- The PDGF/PDGFR pathway as a drug target
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning
- Premature hair graying: a multifaceted phenomenon
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Unusual Presentation of Childhood Leukemia With Vaginal Bleeding: A Case Report
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- The JAK/STAT signaling pathway: from bench to clinic
- Protein Kinase C as a Therapeutic Target
- Costunolide—A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Cutaneous drug reactions
- Flexural Agminated Eruptive Nevi in Langerhans Cell Histiocytosis
- [4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer